Investors purchased shares of Pfizer Inc. (NYSE:PFE) on weakness during trading hours on Monday following insider selling activity. $90.14 million flowed into the stock on the tick-up and $68.22 million flowed out of the stock on the tick-down, for a money net flow of $21.92 million into the stock. Of all companies tracked, Pfizer had the 13th highest net in-flow for the day. Pfizer traded down ($0.07) for the day and closed at $37.13Specifically, EVP Rady A. Johnson sold 8,000 shares of the business’s stock in a transaction on Friday, December 15th. The shares were sold at an average price of $37.07, for a total transaction of $296,560.00. Following the sale, the executive vice president now directly owns 46,963 shares of the company’s stock, valued at approximately $1,740,918.41. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Alexander R. Mackenzie sold 6,750 shares of the business’s stock in a transaction on Friday, December 15th. The shares were sold at an average price of $37.00, for a total transaction of $249,750.00. Following the sale, the insider now directly owns 103,458 shares in the company, valued at $3,827,946. The disclosure for this sale can be found here. Insiders have sold a total of 36,800 shares of company stock valued at $1,327,248 in the last quarter. Insiders own 0.06% of the company’s stock.

Several brokerages have issued reports on PFE. Zacks Investment Research raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $40.00 target price on the stock in a research note on Tuesday, October 3rd. Vetr downgraded shares of Pfizer from a “buy” rating to a “hold” rating and set a $35.71 target price on the stock. in a research note on Wednesday, September 13th. BMO Capital Markets set a $39.00 target price on shares of Pfizer and gave the company a “buy” rating in a research note on Tuesday, October 31st. Sanford C. Bernstein set a $39.00 target price on shares of Pfizer and gave the company a “buy” rating in a research note on Tuesday, September 19th. Finally, Deutsche Bank set a $38.00 target price on shares of Pfizer and gave the company a “buy” rating in a research note on Wednesday, December 6th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and thirteen have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $38.77.

The company has a quick ratio of 1.15, a current ratio of 1.43 and a debt-to-equity ratio of 0.56. The stock has a market capitalization of $221,560.00, a P/E ratio of 14.88, a price-to-earnings-growth ratio of 2.62 and a beta of 1.01.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.02. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The business had revenue of $13.17 billion for the quarter, compared to the consensus estimate of $13.17 billion. During the same period in the prior year, the business posted $0.61 earnings per share. Pfizer’s revenue for the quarter was up .9% compared to the same quarter last year. analysts forecast that Pfizer Inc. will post 2.59 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 1st. Stockholders of record on Friday, February 2nd will be paid a $0.34 dividend. This is an increase from Pfizer’s previous quarterly dividend of $0.32. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.66%. Pfizer’s dividend payout ratio is 78.53%.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Shine Investment Advisory Services Inc. bought a new stake in Pfizer in the second quarter worth $102,000. Mckinley Capital Management LLC Delaware bought a new stake in Pfizer in the second quarter worth $103,000. D. Scott Neal Inc. boosted its holdings in Pfizer by 19.3% in the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 504 shares in the last quarter. Franklin Parlapiano Turner & Welch LLC bought a new stake in Pfizer in the first quarter worth $121,000. Finally, Herndon Capital Management LLC bought a new stake in Pfizer in the second quarter worth $120,000. 69.89% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Traders Buy Shares of Pfizer (PFE) on Weakness Following Insider Selling” was first reported by Watch List News and is the property of of Watch List News. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece can be read at https://www.watchlistnews.com/traders-buy-shares-of-pfizer-pfe-on-weakness-following-insider-selling/1771947.html.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.